Share This Page
Drugs in ATC Class D07XC
✉ Email this page to a colleague
Drugs in ATC Class: D07XC - Corticosteroids, potent, other combinations
ATC D07XC patent landscape and market dynamics for potent topical corticosteroid combinations: who owns the exclusivity, what expires first, and where generics can enter
ATC D07XC (corticosteroids, potent, other combinations) covers topical corticosteroid fixed combinations where the corticosteroid is “potent” and the product pairs it with other actives (commonly antibiotics/antifungals, antiseptics, keratolytics, or other dermatology agents depending on country classification practice). The patent and exclusivity profile is highly country-specific and product-specific. A complete, accurate landscape by product name, Orange Book status (US), EP validation status (EP), and SPC/transition timing requires an identified list of marketed D07XC products and their exact active ingredients.
What patents protect topical corticosteroid potent combinations in ATC D07XC?
Featured-snippet answer: Patent protection typically clusters into (1) product composition (fixed-dose combination), (2) method of preparation, (3) formulation/process claims (carrier system, particle size, solubilization, penetration enhancers), (4) use patents (indication-specific or regimen-specific), and (5) regulatory exclusivities where applicable (US). Where products are reformulations of older actives, the composition claims often anchor the estate; where products are novel fixed combinations, the first filing’s “combination claim” usually sets the baseline exclusivity.
Which patent types dominate for D07XC fixed combinations?
- Composition of matter for the fixed combination
- Covers the pairing of a potent corticosteroid with the co-active (examples by therapeutic intent across markets: antibiotics, antifungals, antiseptics, keratolytics, or other dermatologic agents).
- Formulation patents
- Often claim solvent system, emulsifier package, microemulsion or gel matrix, viscosity range, pH, preservative system, and release/skin penetration characteristics.
- Manufacturing process patents
- Claim mixing order, temperature profile, sterile processing (if relevant), milling/dispersion method, and stability engineering.
- Method-of-use and treatment regimen patents
- Indication and dosing schedule claims for specific dermatologic conditions (e.g., inflammatory dermatoses with secondary infection). These are common when the fixed combination is positioned for “mixed” etiologies rather than pure inflammation.
- Regulatory exclusivities and paediatric extensions (where applicable)
- In the US, marketing exclusivity and data exclusivity can layer on top of patent expiry if the product is NDA/LBMA-derived. In the EU, supplementary protection certificates (SPCs) can extend based on the first marketing authorization.
Key assignees and common filing geographies
For topical combination products across Europe and the US, patent families are typically filed in:
- EP (for broad EU coverage)
- WO under PCT for global priority
- US for enforceable composition/formulation claims
- KR/JP/CN for manufacturing and local enforcement (depends on brand)
Without the specific D07XC branded products and their active ingredients, a definitive “who owns what” mapping is not possible here.
When does ATC D07XC lose exclusivity: patent expiry vs SPC vs data exclusivity?
Featured-snippet answer: In most D07XC combination products, exclusivity ends in layers. Patent expiry (typically 20 years from earliest priority) is usually followed or delayed by SPCs in the EU, and by regulatory exclusivity plus Orange Book-listed patents in the US. Launch timing for generics hinges on the earliest actionable IP listed for the exact dosage form and strength.
Typical timing framework you can use for D07XC products
- Earliest priority filing: sets the theoretical 20-year patent horizon.
- Final dosage form approval date (US/EU): drives potential SPC calculations in the EU.
- US patent listing: Orange Book-listed patents define the “earliest legal launch” if filed as patents for the approved drug product.
- Evergreening risk: later formulation or method-of-use patents can create “evergreen” launch friction if they remain listed and enforceable.
What matters most for topical combinations?
Topical combos often have:
- multiple listed patents covering the specific formulation and fixed combination ratio
- separate patents for different dosage strengths, vehicle types (cream vs ointment vs gel), or co-ingredient embodiments
For a market-access model, the decision driver is the earliest of:
- the last-to-expire composition patent for the fixed ratio
- the last-to-expire formulation patent tied to the approved dosage form
- the last-to-expire SPC in EU jurisdictions
How many patents cover D07XC potent corticosteroid combinations and how strong is the estate?
Featured-snippet answer: D07XC fixed combinations commonly have a medium-to-high patent density per product, with the strongest claims in composition and formulation. Patent strength varies by family scope (EU-wide vs narrow), claim construction risk, and whether later patents are materially distinct from the original invention.
Typical patent estate structure (product-level, not ATC-level)
In the absence of identified product list/INN/brand entries, a defensible count cannot be produced. A complete analysis requires mapping:
- brand-to-ingredient-to-strength
- FDA/EU approvals to determine which patents are tied to which product-specific regulatory dossiers
- jurisdiction-by-jurisdiction enforceability and SPC coverage
What is the Orange Book status of ATC D07XC topical corticosteroid combinations?
Featured-snippet answer: Orange Book status is only meaningful product-by-product. D07XC as an ATC code is not Orange Book searchable without the underlying US active ingredient and approved drug product identifiers. The Orange Book listing typically includes patents in categories such as:
- Drug substance
- Drug product
- Method of use
- Orphan (rare in this therapeutic area) For each D07XC product, the Orange Book listing determines:
- which patents are eligible for Paragraph IV
- which patents must be respected for generic launch
- whether a settlement caps launch dates
No product identifiers were provided, so a correct Orange Book enumeration cannot be generated.
Which companies are challenging D07XC topical corticosteroid patents via Paragraph IV?
Featured-snippet answer: Paragraph IV challenges are also product-specific. Companies that file Paragraph IV are typically generic and specialty generics with dermatology portfolios, but the exact challengers depend on which D07XC products have US approvals and listed patents.
A defensible list requires:
- the D07XC product names
- their approved US drug product identifiers
- associated Orange Book “patent with NDA/BLA”
Without that, generating a challenger list would be inaccurate.
What patent litigation affects topical corticosteroid potent combination products?
Featured-snippet answer: Litigation affects launch through:
- injunction risk
- settlement agreements that lock in “carve-out” launch dates or market-share caps
- noninfringement/invalidity outcomes that determine whether generics can proceed at risk
Litigation pattern by patent type
- Composition patents drive the bulk of disputes when the fixed combination ratio is central.
- Formulation patents drive disputes when vehicle, solubilizers, or penetration system are critical.
- Method-of-use patents can create disputes around label carve-outs and “skin indication” claims.
No D07XC product list was provided, so litigation events cannot be mapped reliably.
How do D07XC topical corticosteroid combinations compare: brand vs generic entry risks
Featured-snippet answer: The generic entry risk profile is usually highest when:
- the brand’s remaining patents include formulation-specific claims tied to the approved vehicle
- the product has a narrow therapeutic profile requiring stable dispersion/particle size
- method-of-use patents constrain label design
- the brand has active litigation or settlement restrictions
Lower entry risk appears when:
- patents are narrow and distinguishable by vehicle or ratio
- formulation patents are invalid/expired
- the product is not listed in the jurisdiction used for the launch strategy
A comparative risk model again depends on identifying the exact marketed products and their patent estates.
What formulations are protected by D07XC patents: creams, ointments, gels, and fixed ratios?
Featured-snippet answer: Patent coverage in D07XC combinations is frequently tied to:
- vehicle (cream vs ointment vs gel)
- pH and preservative system
- solubilization system and emulsifier package
- viscosity and rheology profile
- penetration enhancer choices
- stability constraints (shelf-life with heat/light/oxidation)
Dosage form-specific blockers generics face
- If the brand patent claims the vehicle system: generics may have to change excipients beyond typical bioequivalence latitude.
- If the patent claims particle dispersion: substitution of milling/dispersion steps may be needed to design around.
- If the patent claims a specific fixed-ratio composition: generics must match ratios to be “equivalent,” which typically triggers combination composition claims.
These are formulation-level issues that require the actual patent documents for each D07XC branded product.
What regulatory status drives exclusivity for D07XC: FDA pathway and EU marketing authorization?
Featured-snippet answer: Exclusivity depends on whether the product was approved via an NDA, ANDA reliance path, and whether it has orphan or data exclusivity triggers. In the EU, authorization type and the availability of an SPC determine extension potential.
Key regulatory levers
- US: Orange Book patent listing plus 505(b)(1)/505(b)(2) or 505(j) pathway availability.
- EU: Marketing authorisation and SPC eligibility based on approval date and regulatory reference products.
- Local: Some markets treat topical combination products differently in classification and exclusivity triggers.
A correct regulatory mapping requires product identifiers and approval dates.
What generic entry scenarios exist for ATC D07XC combinations?
Featured-snippet answer: A generic can enter via:
- Patent-expired launch: after earliest actionable patent expiry/SPC.
- At-risk launch: after a Paragraph IV ANDA if litigation is pending and the court does not stay or does not enjoin.
- Settlement-based launch: post-settlement at date(s) agreed with the brand, sometimes with carve-outs.
- Label carve-out: if disputes are over method-of-use claims, generics may launch with narrower labeling.
The choice among these scenarios is driven by the specific patent list and the jurisdiction of first launch.
How does D07XC patent strategy differ across EU vs US?
Featured-snippet answer: US strategy is governed by Orange Book listed patents and Paragraph IV framework. EU strategy is governed by EP validation scope and SPC availability, then by national enforcement for the remaining term.
US vs EU practical differences for topical combinations
- US: patent listing category and “approved drug product” scope can make vehicle and formulation patents enforceable against generic product presentation.
- EU: SPC can extend the economic life even after base patent expiry, and national courts determine enforcement timelines.
A US-EU comparative table cannot be produced without product identification.
Key Takeaways
- ATC D07XC is too broad for a complete, accurate patent landscape without mapping to specific branded or approved products with their exact active ingredients and dosage forms.
- For topical potent corticosteroid combinations, the decisive IP usually sits in fixed combination composition claims and vehicle/formulation patents, with EU SPC and US Orange Book listing as the main exclusivity layers.
- Generic entry risk is highest when formulation-specific and fixed-ratio composition patents remain enforceable and are actively litigated or settlement-protected.
- A defensible “who owns what” answer for D07XC requires product-level identifiers to connect approvals, patent lists, SPC/term, and litigation records.
FAQs
- Which D07XC topical corticosteroid combinations have EU SPC extensions and for which active ingredients?
- How do formulation patents in topical corticosteroid combination products affect generic bioequivalence and design-around strategies?
- What label carve-outs are commonly negotiated in litigation involving topical corticosteroid fixed combinations?
- Do D07XC products typically face Paragraph IV challenges in the US, and what filing strategies drive settlement outcomes?
- How does dosage-form switching (cream vs ointment vs gel) impact infringement risk for D07XC combination formulations?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via public FDA database).
- European Medicines Agency. Supplementary Protection Certificate (SPC) information and guidance. (EMA public materials).
More… ↓
